Skip to main content
Top
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington’s disease

Authors: Lucy M Collins, Stanley E Lazic, Roger A Barker

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

Current clinical assessments of motor function in Huntington’s Disease (HD) rely on subjective ratings such as the Unified Huntington’s Disease Rating scale (UHDRS). The ability to track disease progression using simple, objective, inexpensive, and robust measures would be beneficial.

Methods

One objective measure of motor performance is hand-tapping. Over the last 14 years we have routinely collected, using a simple device, the number of taps made by the right and left hand over 30 seconds in HD patients attending our NHS clinics.

Results

Here we report on a longitudinal cohort of 237 patients, which includes patients at all stages of the disease on a wide range of drug therapies. Hand tapping in these patients declines linearly at a rate of 5.1 taps per year (p < 0.0001; 95% CI = 3.8 to 6.3 taps), and for each additional year of age patients could perform 0.9 fewer taps (main effect of age: p = 0.0007; 95% CI = 0.4 to 1.4). Individual trajectories can vary widely around this average rate of decline, and much of this variation could be attributed to CAG repeat length. Genotype information was available for a subset of 151 patients, and for each additional repeat, patients could perform 5.6 fewer taps (p < 0.0001; 95% CI = 3.3 to 8.0 taps), and progressed at a faster rate of 0.45 fewer taps per year (CAG by time interaction: p = 0.008; 95% CI = 0.12 to 0.78 taps). In addition, for each unit decrease in Total Functional Capacity (TFC) within individuals, the number of taps decreased by 6.3 (95% CI = 5.4 to 7.1, p < 0.0001).

Conclusions

Hand tapping is a simple, robust, and reliable marker of disease progression. As such, this simple motor task could be a useful tool by which to assess disease progression as well therapies designed to slow it down.
Appendix
Available only for authorised users
Literature
1.
go back to reference MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, Bates GP, Baxendale S, Hummerich H, Kirby S, North M, Youngman S, Mott R, Zehetner G, SEDLACEK Z, Poustka A, Frischauf AM, Lehrach H, Buckler AJ, Church D, Doucettestamm L, et al: A novel gene containing a trinucleotide repeat that is expanded and unstable on huntingtons-disease chromosomes. Cell. 1993, 72: 971-983. 10.1016/0092-8674(93)90585-E.CrossRef MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, Bates GP, Baxendale S, Hummerich H, Kirby S, North M, Youngman S, Mott R, Zehetner G, SEDLACEK Z, Poustka A, Frischauf AM, Lehrach H, Buckler AJ, Church D, Doucettestamm L, et al: A novel gene containing a trinucleotide repeat that is expanded and unstable on huntingtons-disease chromosomes. Cell. 1993, 72: 971-983. 10.1016/0092-8674(93)90585-E.CrossRef
2.
go back to reference Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB: Differential loss of striatal projection neurons in huntington disease. Proc Natl Acad Sci U S A. 1988, 85: 5733-5737. 10.1073/pnas.85.15.5733.CrossRefPubMedPubMedCentral Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB: Differential loss of striatal projection neurons in huntington disease. Proc Natl Acad Sci U S A. 1988, 85: 5733-5737. 10.1073/pnas.85.15.5733.CrossRefPubMedPubMedCentral
3.
go back to reference Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM: Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2003, 60: 1615-1620. 10.1212/01.WNL.0000065888.88988.6E.CrossRefPubMed Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM: Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2003, 60: 1615-1620. 10.1212/01.WNL.0000065888.88988.6E.CrossRefPubMed
4.
go back to reference Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD Investigators: Biological and clinical manifestations of huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8: 791-801. 10.1016/S1474-4422(09)70170-X.CrossRefPubMedPubMedCentral Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD Investigators: Biological and clinical manifestations of huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8: 791-801. 10.1016/S1474-4422(09)70170-X.CrossRefPubMedPubMedCentral
5.
go back to reference Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, TRACK-HD Investigators: Biological and clinical changes in premanifest and early stage huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011, 10: 31-42. 10.1016/S1474-4422(10)70276-3.CrossRefPubMed Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, TRACK-HD Investigators: Biological and clinical changes in premanifest and early stage huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011, 10: 31-42. 10.1016/S1474-4422(10)70276-3.CrossRefPubMed
6.
go back to reference Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM: Objective assessment of progression in huntington’s disease: a 3-year follow-up study. Neurology. 2001, 57: 920-924. 10.1212/WNL.57.5.920.CrossRefPubMed Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM: Objective assessment of progression in huntington’s disease: a 3-year follow-up study. Neurology. 2001, 57: 920-924. 10.1212/WNL.57.5.920.CrossRefPubMed
7.
go back to reference Beste C, Stock AK, Ness V, Hoffmann R, Lukas C: A novel cognitive-neurophysiological state biomarker in premanifest huntington’s disease validated on longitudinal data. Sci Reports. 2013, 3: 1797- Beste C, Stock AK, Ness V, Hoffmann R, Lukas C: A novel cognitive-neurophysiological state biomarker in premanifest huntington’s disease validated on longitudinal data. Sci Reports. 2013, 3: 1797-
8.
go back to reference Stout JC, Jones R, Labuschagne I, O’Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Durr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C: Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early huntington’s disease. J Neurol Neurosurg Psychiatry. 2012, 83: 687-694. 10.1136/jnnp-2011-301940.CrossRefPubMedPubMedCentral Stout JC, Jones R, Labuschagne I, O’Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Durr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C: Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early huntington’s disease. J Neurol Neurosurg Psychiatry. 2012, 83: 687-694. 10.1136/jnnp-2011-301940.CrossRefPubMedPubMedCentral
9.
go back to reference Tabrizi SJ, Reilmann R, Roos RAC, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD Investigators: Potential endpoints for clinical trials in premanifest and early huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012, 11: 42-53. 10.1016/S1474-4422(11)70263-0.CrossRefPubMed Tabrizi SJ, Reilmann R, Roos RAC, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD Investigators: Potential endpoints for clinical trials in premanifest and early huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012, 11: 42-53. 10.1016/S1474-4422(11)70263-0.CrossRefPubMed
10.
go back to reference Clabough E: Huntington’s disease: the past, present, and future search for disease modifiers. Yale J Biol Med. 2013, 86: 217-233.PubMedPubMedCentral Clabough E: Huntington’s disease: the past, present, and future search for disease modifiers. Yale J Biol Med. 2013, 86: 217-233.PubMedPubMedCentral
11.
go back to reference Kremer H: Unified huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996, 11: 136-142.CrossRef Kremer H: Unified huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996, 11: 136-142.CrossRef
12.
go back to reference Weir DW, Sturrock A, Leavitt BR: Development of biomarkers for huntington’s disease. Lancet Neurol. 2011, 10: 573-590. 10.1016/S1474-4422(11)70070-9.CrossRefPubMed Weir DW, Sturrock A, Leavitt BR: Development of biomarkers for huntington’s disease. Lancet Neurol. 2011, 10: 573-590. 10.1016/S1474-4422(11)70070-9.CrossRefPubMed
13.
go back to reference Rupp J, Blekher T, Jackson J, Beristain X: Progression in prediagnostic huntington disease. J Neurol. 2010, 81: 379-384. Rupp J, Blekher T, Jackson J, Beristain X: Progression in prediagnostic huntington disease. J Neurol. 2010, 81: 379-384.
14.
go back to reference Thompson JC, Poliakoff E, Sollom AC, Howard E: Automaticity and attention in huntington’s disease: when two hands are not better than one. Neuropsychologia. 2010, 48: 171-178. 10.1016/j.neuropsychologia.2009.09.002.CrossRefPubMed Thompson JC, Poliakoff E, Sollom AC, Howard E: Automaticity and attention in huntington’s disease: when two hands are not better than one. Neuropsychologia. 2010, 48: 171-178. 10.1016/j.neuropsychologia.2009.09.002.CrossRefPubMed
15.
go back to reference Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, Predict-HD Investigators and Coordinators of the Huntington Study Group: Detection of huntington’s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry. 2008, 79: 874-880. 10.1136/jnnp.2007.128728.CrossRefPubMed Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, Predict-HD Investigators and Coordinators of the Huntington Study Group: Detection of huntington’s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry. 2008, 79: 874-880. 10.1136/jnnp.2007.128728.CrossRefPubMed
16.
go back to reference Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, TRACK-HD Investigators: Predictors of phenotypic progression and disease onset in premanifest and early-stage huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013, 12: 637-649. 10.1016/S1474-4422(13)70088-7.CrossRefPubMed Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, TRACK-HD Investigators: Predictors of phenotypic progression and disease onset in premanifest and early-stage huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013, 12: 637-649. 10.1016/S1474-4422(13)70088-7.CrossRefPubMed
17.
go back to reference Rowe KC, Paulsen JS, Langbehn DR, Duff K: Self-paced timing detects and tracks change in prodromal huntington disease. Neuropsychology. 2010, 24: 435-442.CrossRefPubMedPubMedCentral Rowe KC, Paulsen JS, Langbehn DR, Duff K: Self-paced timing detects and tracks change in prodromal huntington disease. Neuropsychology. 2010, 24: 435-442.CrossRefPubMedPubMedCentral
18.
go back to reference Michell AW, Goodman AOG, Silva AHD, Lazic SE, Morton AJ, Barker RA: Hand tapping: a simple, reproducible, objective marker of motor dysfunction in huntington’s disease. J Neurol. 2008, 255: 1145-1152. 10.1007/s00415-008-0859-x.CrossRefPubMed Michell AW, Goodman AOG, Silva AHD, Lazic SE, Morton AJ, Barker RA: Hand tapping: a simple, reproducible, objective marker of motor dysfunction in huntington’s disease. J Neurol. 2008, 255: 1145-1152. 10.1007/s00415-008-0859-x.CrossRefPubMed
19.
go back to reference Blekher T, Johnson SA, Marshall J, White K, Hui S: Saccades in presymptomatic and early stages of huntington disease. Neurology. 2006, 67: 394-399. 10.1212/01.wnl.0000227890.87398.c1.CrossRefPubMed Blekher T, Johnson SA, Marshall J, White K, Hui S: Saccades in presymptomatic and early stages of huntington disease. Neurology. 2006, 67: 394-399. 10.1212/01.wnl.0000227890.87398.c1.CrossRefPubMed
20.
go back to reference Antoniades CA, Xu Z, Mason SL, Carpenter RHS, Barker RA: Huntington’s disease: changes in saccades and hand-tapping over 3 years. J Neurol. 2010, 257: 1890-1898. 10.1007/s00415-010-5632-2.CrossRefPubMed Antoniades CA, Xu Z, Mason SL, Carpenter RHS, Barker RA: Huntington’s disease: changes in saccades and hand-tapping over 3 years. J Neurol. 2010, 257: 1890-1898. 10.1007/s00415-010-5632-2.CrossRefPubMed
21.
go back to reference Andrich J, Saft C, Ostholt N, Müller T: Complex movement behaviour and progression of huntington’s disease. Neurosci Lett. 2007, 416: 272-274. 10.1016/j.neulet.2007.02.027.CrossRefPubMed Andrich J, Saft C, Ostholt N, Müller T: Complex movement behaviour and progression of huntington’s disease. Neurosci Lett. 2007, 416: 272-274. 10.1016/j.neulet.2007.02.027.CrossRefPubMed
22.
go back to reference Saft C, Andrich J, Meisel NM, Przuntek H, Müller T: Assessment of complex movements reflects dysfunction in huntington’s disease. J Neurol. 2003, 250: 1469-1474. 10.1007/s00415-003-0256-4.CrossRefPubMed Saft C, Andrich J, Meisel NM, Przuntek H, Müller T: Assessment of complex movements reflects dysfunction in huntington’s disease. J Neurol. 2003, 250: 1469-1474. 10.1007/s00415-003-0256-4.CrossRefPubMed
23.
go back to reference Müller T, Saft C, Andrich J, Harati A: Diadochokinetic movements differ between patients with huntington’s disease and controls. NeuroRehabilitation. 2013, 33: 649-655.PubMed Müller T, Saft C, Andrich J, Harati A: Diadochokinetic movements differ between patients with huntington’s disease and controls. NeuroRehabilitation. 2013, 33: 649-655.PubMed
24.
go back to reference Goldberg YP, Andrew SE, Clarke LA, Hayden MR: A PCR method for accurate assessment of trinucleotide repeat expansion in huntington disease. Hum Mol Genet. 1993, 6: 635-636.CrossRef Goldberg YP, Andrew SE, Clarke LA, Hayden MR: A PCR method for accurate assessment of trinucleotide repeat expansion in huntington disease. Hum Mol Genet. 1993, 6: 635-636.CrossRef
25.
go back to reference Shoulson I, Fahn S: Huntington disease clinical care and evaluation. Neurology. 1979, 29: 1-3. 10.1212/WNL.29.1.1.CrossRefPubMed Shoulson I, Fahn S: Huntington disease clinical care and evaluation. Neurology. 1979, 29: 1-3. 10.1212/WNL.29.1.1.CrossRefPubMed
26.
go back to reference Shoulson I: Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981, 31: 1333-1335. 10.1212/WNL.31.10.1333.CrossRefPubMed Shoulson I: Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981, 31: 1333-1335. 10.1212/WNL.31.10.1333.CrossRefPubMed
27.
go back to reference Saft C, Andrich J, Meisel N-M, Przuntek H, Müller T: Assessment of simple movements reflects impairment in huntington’s disease. Mov Disord. 2006, 21: 1208-1212. 10.1002/mds.20939.CrossRefPubMed Saft C, Andrich J, Meisel N-M, Przuntek H, Müller T: Assessment of simple movements reflects impairment in huntington’s disease. Mov Disord. 2006, 21: 1208-1212. 10.1002/mds.20939.CrossRefPubMed
28.
go back to reference Andrich J, Saft C, Ostholt N, Müller T: Assessment of simple movements and progression of huntington’s disease. J Neurol Neurosurg Psychiatry. 2007, 78: 405-407.CrossRefPubMed Andrich J, Saft C, Ostholt N, Müller T: Assessment of simple movements and progression of huntington’s disease. J Neurol Neurosurg Psychiatry. 2007, 78: 405-407.CrossRefPubMed
29.
go back to reference Maroof DA, Gross AL, Brandt J: Modeling longitudinal change in motor and cognitive processing speed in presymptomatic huntington’s disease. J Clin Exp Neuropsychol. 2011, 33: 901-909. 10.1080/13803395.2011.574606.CrossRefPubMed Maroof DA, Gross AL, Brandt J: Modeling longitudinal change in motor and cognitive processing speed in presymptomatic huntington’s disease. J Clin Exp Neuropsychol. 2011, 33: 901-909. 10.1080/13803395.2011.574606.CrossRefPubMed
30.
go back to reference Kirkwood SC, Siemers E, Bond C, Conneally PM, Christian JC, Foroud T: Confirmation of subtle motor changes among presymptomatic carriers of the huntington disease gene. Arch Neurol. 2000, 57: 1040-1044. 10.1001/archneur.57.7.1040.CrossRefPubMed Kirkwood SC, Siemers E, Bond C, Conneally PM, Christian JC, Foroud T: Confirmation of subtle motor changes among presymptomatic carriers of the huntington disease gene. Arch Neurol. 2000, 57: 1040-1044. 10.1001/archneur.57.7.1040.CrossRefPubMed
31.
go back to reference Jenkins M, Flynn A, Smart T, Harbron C, Sabin T, Ratnayake J, Delmar P, Herath A, Jarvis P, Matcham J, PSI Biomarker Special Interest Group: A statistician’s perspective on biomarkers in drug development. Pharm Stat. 2011, 10: 494-507. 10.1002/pst.532.CrossRefPubMed Jenkins M, Flynn A, Smart T, Harbron C, Sabin T, Ratnayake J, Delmar P, Herath A, Jarvis P, Matcham J, PSI Biomarker Special Interest Group: A statistician’s perspective on biomarkers in drug development. Pharm Stat. 2011, 10: 494-507. 10.1002/pst.532.CrossRefPubMed
Metadata
Title
A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington’s disease
Authors
Lucy M Collins
Stanley E Lazic
Roger A Barker
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-35

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue